The most talked-about unapproved peptide in the world, on the strength of a mid-stage trial and very little else.
what it is
Retatrutide adds a third receptor to the incretin formula: glucagon. That sounds counterintuitive, since glucagon raises blood sugar, but glucagon receptor activation also increases energy expenditure. The bet is that the GLP-1 and GIP components offset the glycaemic downside while the glucagon component adds a metabolic-rate effect the others do not have.
what the evidence shows
A phase 2 trial reported mean weight reduction around twenty-four per cent at forty-eight weeks at the highest dose, with the curve still descending at the end of the study. That result is why the compound is discussed the way it is. Phase 3 programmes are running. No regulator anywhere has approved it for any indication.
The most talked-about unapproved peptide in the world, on the strength of a mid-stage trial and very little else.
what stays uncertain
Almost everything that matters. Phase 2 establishes a signal; phase 3 establishes whether it holds in larger, more varied populations and what turns up at low frequency. Dose-dependent heart rate increases have been observed across this class and the glucagon arm raises specific questions. There is no long-term human safety dataset because there has not yet been time to build one.
the practical note
Retatrutide is widely sold by research-chemical vendors, which means material of unverified identity and purity is being used by people at doses extrapolated from a trial abstract. This is the single widest gap between public enthusiasm and available evidence anywhere in the peptide field.